• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 8:49:14 AM ET
    $BRPA
    Business Services
    Finance
    Get the next $BRPA alert in real time by email
    SC 13G/A 1 brpaa1_21621.htm OXFORD ASSET MANAGEMENT LLP brpaa1_21621.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    Big Rock Partners Acquisition Corp.
    (Name of Issuer)
    Common stock, par value $0.001
    (Title of Class of Securities)
    089482103
    (CUSIP Number)
    December 31, 2020
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 089482103
           
    1
    NAME OF REPORTING PERSON
    OxFORD ASSET MANAGEMENT LLP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    UNITED KINGDOM
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 089482103
    ITEM 1(a). NAME OF ISSUER:
    Big Rock Partners Acquisition Corp.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    2645 N.Federal Highway, Suite 230
    Delray Beach, FL
    ITEM 2(a). NAME OF PERSON FILING:
    This Amendment No.1 amends and supplements the statement on Schedule 13G filed with the Securities and Exchange Commission on February 13, 2020 (the "Original Schedule 13G") and is filed on behalf of OxFORD Asset Management LLP ("OxFORD").

    This Statement relates to Shares (as defined herein) held for the account of OxAM Quant Fund Limited, a Cayman Islands exempted company ("OxAM"). OxFORD serves as investment adviser to OxAM. In such capacity, OxFORD may be deemed to exercise the voting and dispositive power over the Shares held for the account of OxAM.
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    OxAM House, 6 George Street, Oxford, United Kingdom, OX1 2BW
    ITEM 2(c). CITIZENSHIP:
    OxFORD is a limited liability partnership incorporated in England and Wales.
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common stock, par value $0.001
    ITEM 2(e). CUSIP NUMBER:
    089482103
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    Item 4(a) of the Original Schedule 13G is hereby amended as follows:

    As of December 31st, 2020, the Reporting Person may be deemed the beneficial owner of 0
    Shares held for the account of OxAM.
    (b) Percent of class:
    Item 4(b) of the Original Schedule 13G is hereby amended as follows:

    As of December 31st, 2020, the Reporting Person may be deemed the beneficial owner of 0.00% of Shares outstanding.
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    0
    (ii) shared power to vote or to direct the vote:
    0
    (iii) sole power to dispose or direct the disposition of:
    0
    (iv) shared power to dispose or to direct the disposition of:
    0
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    See disclosure in Items 2 and 4 hereof. OxAM has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Person.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    This Item 7 is not applicable.
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    This Item 8 is not applicable.
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    This Item 9 is not applicable.
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 089482103
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 16 2021
    OxFORD ASSET MANAGEMENT LLP
    By:
    /s/ Mark Garfield
    Name:
    Mark Garfield
    Title:
    Chief Compliance Officer
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $BRPA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRPA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BRPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: BRAC Lending Group LLC returned 869,565 units of Common Stock to the company, decreasing direct ownership by 60% to 590,435 units (Amendment)

    4/A - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    6/4/21 9:40:44 AM ET
    $BRPA
    Business Services
    Finance

    SEC Form 4 filed by Big Rock Partners Acquisition Corp.

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    5/25/21 9:17:34 PM ET
    $BRPA
    Business Services
    Finance

    SEC Form 4 filed by Big Rock Partners Acquisition Corp.

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    5/25/21 8:02:21 PM ET
    $BRPA
    Business Services
    Finance

    $BRPA
    SEC Filings

    View All

    SEC Form 8-K filed by Big Rock Partners Acquisition Corp.

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    5/28/21 5:26:36 PM ET
    $BRPA
    Business Services
    Finance

    Big Rock Partners Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Change in Shell Company Status

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    5/28/21 5:26:03 PM ET
    $BRPA
    Business Services
    Finance

    SEC Form 8-K filed by Big Rock Partners Acquisition Corp.

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    5/26/21 4:13:58 PM ET
    $BRPA
    Business Services
    Finance

    $BRPA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

    RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ:NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM Eastern Time to discuss its business update and second quarter financial results. "NRx is pleased to report its first quarterly results as a publicly-traded company. We have continued to make substantial progress as a company with the filing of an EUA request for ZYESAMI in the US on May 31st, and the filing and granting of an EUA in the Nation of Georgia, with first orders expected shortly. We are honored to

    8/16/21 9:32:00 PM ET
    $BRPA
    $NRXP
    Business Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)

    RADNOR, Pa., May 25, 2021 /PRNewswire/ -- Today, NeuroRx, Inc., announced it has been approved by the Nasdaq for listing on the Nasdaq Global Market, following the completion of its business combination with Big Rock Partners Acquisition Corp. (NASDAQ:BRPA). The combined entity is NRx Pharmaceuticals, Inc. and will trade on the Nasdaq Global Market as NRXP. NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP"Today marks a major milestone as we include public investors in our quest to bring innovative medicines to patients at immediate risk of death, who have no curr

    5/25/21 6:48:00 AM ET
    $BRPA
    Business Services
    Finance

    Big Rock Partners Acquisition Corp. Announces Effectiveness of Registration Statement; Confirms Annual Meeting Date of May 24, 2021 to Approve Proposed Merger with NeuroRx

    Big Rock Partners Recommends All Stockholders Vote "FOR" ALL Proposals at Annual Meeting NEW YORK, NY / ACCESSWIRE / May 21, 2021 / Big Rock Partners Acquisition Corp. ("Big Rock" or "BRPA") (NASDAQ:BRPA), a publicly traded special purpose acquisition company, today confirmed that its Annual Meeting of Stockholders (the "Annual Meeting") to consider the previously announced merger agreement with NeuroRx, Inc. ("NeuroRx" or the "Company") will take place on May 24, 2021. Stockholders of record as of April 23, 2021 (the "Record Date") are eligible to vote at the Annual Meeting.Big Rock also announced that the U.S. Securities and Exchange Commission has declared effective its registration state

    5/21/21 6:40:00 PM ET
    $BRPA
    Business Services
    Finance

    $BRPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Big Rock Partners Acquisition Corp. (Amendment)

    SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    6/4/21 10:17:16 AM ET
    $BRPA
    Business Services
    Finance

    SEC Form SC 13D filed by Big Rock Partners Acquisition Corp.

    SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    6/3/21 5:30:14 PM ET
    $BRPA
    Business Services
    Finance

    SEC Form SC 13D/A filed by Big Rock Partners Acquisition Corp. (Amendment)

    SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    5/26/21 5:02:30 PM ET
    $BRPA
    Business Services
    Finance

    $BRPA
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

    RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ:NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM Eastern Time to discuss its business update and second quarter financial results. "NRx is pleased to report its first quarterly results as a publicly-traded company. We have continued to make substantial progress as a company with the filing of an EUA request for ZYESAMI in the US on May 31st, and the filing and granting of an EUA in the Nation of Georgia, with first orders expected shortly. We are honored to

    8/16/21 9:32:00 PM ET
    $BRPA
    $NRXP
    Business Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care